1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 71 results for "Myelodysplastic Syndromes (MDS)".

$Thumbnail for Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results$

MDS - 812

Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results

Amit Verma

Poster Presenter: Amit Verma

Thumbnail for Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

MDS - 819

Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

Jeremiah Bearss

SOHO 2026 Annual Meeting

Topics

Ofirnoflast (HT-6184), a First-in-Class Allosteric NEK7 Inhibitor, Achieves Durable Transfusion Independence (TI) and Hematological Improvement-Erythroid (HI-E) in ESA-Refractory Lower-Risk Myelodysplastic Syndrome (LR-MDS): Phase 2 Final Results

Multilineage Hematologic Improvement in Lower-Risk Myelodysplastic Syndromes: Clinical Significance of Platelet and Neutrophil Recovery With Ofirnoflast, a Potent Allosteric Inhibitor of NEK7/NLRP3 Assembly

Elritercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naοve adults with lower-risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia: The ELRiSE MDS phase 3 study

Allosteric NEK7 Inhibition With Ofirnoflast (HT-6184) Suppresses Mitochondrial Stress, Reduces Systemic Inflammatory Cytokines, and Attenuates Clonal Expansion in Lower-Risk Myelodysplastic Syndrome

Updated Phase 2 Results of Elritercept in Patients With Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms

Racial and Ethnic Disparities in Acute Myeloid Leukemia Transformation After Myelodysplastic Syndrome: A Population-Based Analysis of Incidence and Latency

Venetoclax Plus Hypomethylating Agent Improves Response Rates in High-Blast TP53-Mutated Myelodysplastic Syndromes

Clinical and Prognostic Impact of CEBPA Mutations in Myelodysplastic Syndromes